In terms of slowing the deterioration in global functioning of people with dementia, anti-cholinesterase drugs have been shown to be cost-effective in both the early and moderate stages of Alzheimer’s disease [31], with recent evidence showing benefit also in advanced stages [32]. The gene discussed is BCHE; the disease is Alzheimer disease.